Last reviewed · How we verify
NCT06971666: DIP
Dietary Inflammatory Potential in Young Pleople With Obesity
trial in Obesity in 170 participants. Not yet recruiting.
22 November 2026
Quick facts
| Lead sponsor | Instituto Tecnológico y de Estudios Superiores de Occidente |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 170 |
| Start date | 20 June 2025 |
| Primary completion | 22 November 2026 |
| Estimated completion | 7 January 2027 |
Conditions studied
- Obesity — all drugs for Obesity →
- Dietary Inflammatory Index (DII) — all drugs for Dietary Inflammatory Index (DII) →
Sponsor
Instituto Tecnológico y de Estudios Superiores de Occidente
Who can join
Adults 18 to 24, any sex, with Obesity or Dietary Inflammatory Index (DII). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The increase in adipose tissue in the young population is one of the most important and worrying public health problems because it persists in adulthood, constituting a risk factor for chronic degenerative diseases with social, economic, and environmental effects. The etiology of obesity is multifactorial and is associated with a low-intensity chronic inflammation process. Therefore, side effects of the digestive, nervous, endocrine, and immunological levels are closely related. Thus, understanding the impact of dietary components on the immune response and the pathophysiological complications of obesity will strengthen information on nutritional patterns with lower inflammatory implications.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06971666
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Obesity
Currently open trials in the same condition.
- NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
- NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
- NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
- NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
- NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting
Other Instituto Tecnológico y de Estudios Superiores de Occidente trials
Trials by the same sponsor.
- NCT05774613 — Effect of Hibiscus Sabdariffa Beverage · NA · unknown
- NCT05210023 — Nutrigenetic Intervention on Blood Lipid Markers and Body Composition of Adults With Overweight and Obesity · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06971666 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Instituto Tecnológico y de Estudios Superiores de Occidente
- Last refreshed: 14 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06971666.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing